We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
Cap. Flow
-$118M
Cap. Flow %
-3.94%
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$40.3M
2
ARGX icon
argenx
ARGX
+$39.9M
3
RVMD icon
Revolution Medicines
RVMD
+$39.2M
4
IMVT icon
Immunovant
IMVT
+$29.2M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$16.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.3M
2
VIR icon
Vir Biotechnology
VIR
+$48M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$46.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$35.7M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$337M 11.23%
27,692,917
+30,000
+0.1% +$387K
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$220M 7.35%
10,088,385
– –
IMVT icon
3
Immunovant
IMVT
$8.99B
$146M 4.88%
3,814,691
+1,290,908
+51% +$29.2M
ACLX
4
DELISTED
Arcellx
ACLX
$142M 4.75%
3,965,978
-50,419
-1% -$1.74M
NUVL
5
DELISTED
Nuvalent
NUVL
$113M 3.78%
2,463,451
+268,630
+12% +$11.9M
SLNO
6
DELISTED
Soleno Therapeutics
SLNO
$90.7M 3.03%
3,074,542
+866,789
+39% +$5.25M
LIAN
7
DELISTED
LianBio American Depositary Shares
LIAN
$85.8M 2.86%
57,558,451
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$81.9M 2.73%
1,619,425
-321,250
-17% -$15M
INBX
9
DELISTED
Inhibrx, Inc. Common Stock
INBX
$78.1M 2.61%
4,256,104
+631,922
+17% +$13.2M
ALDX icon
10
Aldeyra Therapeutics
ALDX
$93.5M
$75.8M 2.53%
11,350,085
– –
ARGX icon
11
argenx
ARGX
$63.8B
$74M 2.47%
150,600
+81,600
+118% +$39.9M
PCVX icon
12
Vaxcyte
PCVX
$9.09B
$68.5M 2.28%
1,342,751
-271,371
-17% -$13.4M
VRNA
13
DELISTED
Verona Pharma
VRNA
$65.3M 2.18%
4,007,197
-389,919
-9% -$7.51M
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$60.3M 2.01%
4,043,191
+309,936
+8% +$4.11M
MGTX icon
15
MeiraGTx Holdings
MGTX
$1.43B
$55.6M 1.86%
11,331,103
– –
IOVA icon
16
Iovance Biotherapeutics
IOVA
$3.82B
$54.4M 1.82%
11,962,938
-2,073,472
-15% -$13.5M
LYRA
17
DELISTED
LYRA THERAPEUTICS INC
LYRA
$49.9M 1.66%
255,151
– –
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$4.17B
$49.2M 1.64%
2,688,873
-2,185,046
-45% -$46.2M
BBIO icon
19
BridgeBio Pharma
BBIO
$15.7B
$46.1M 1.54%
1,748,933
– –
MDT icon
20
Medtronic
MDT
$117B
$46M 1.53%
587,000
+120,000
+26% +$10M
ROIV icon
21
Roivant Sciences
ROIV
$26.3B
$44.6M 1.49%
3,819,456
+687,720
+22% +$7.77M
IRON icon
22
Disc Medicine
IRON
$3.16B
$42.1M 1.4%
895,641
+152,803
+21% +$7.64M
IMTX icon
23
Immatics
IMTX
$1.26B
$40.4M 1.35%
3,491,500
– –
APGE icon
24
Apogee Therapeutics
APGE
$10.2B
$38.9M 1.3%
+1,827,901
New +$40.3M
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$9B
$37.6M 1.25%
1,263,732
-683,205
-35% -$14.1M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $118M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.

  • Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
  • Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
  • Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
  • Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
  • Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
  • Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.